2. Disease Areas
  3. Cancer Digestive System Disease
  4. Colorectal Cancer Digestive System Cancer
  5. Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Metastatic colorectal cancer (mCRC) is a lethal disease with a 5-year survival rate of approximately 14%, primarily due to the widespread dissemination of therapy-resistant cancer cells that drive metastasis. While early-stage colorectal cancer can often be cured with surgery and/or adjuvant chemotherapy, mCRC remains incurable because of the persistence and resilience of metastasis-competent cells. Advances in genomic technologies—including whole-genome and single-cell sequencing, CRISPR/Cas9 gene editing, and transgenic mouse models—have significantly enhanced our understanding of the molecular mechanisms underlying CRC metastasis. These insights have facilitated the development of targeted therapies and immunotherapies that offer alternatives to conventional chemotherapy by reducing cytotoxicity and overcoming resistance. Numerous reviews summarize current targeted agents and immunotherapeutic approaches for mCRC.

Metastatic Colorectal Cancer (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183278
    APO-50815
    APO-50815 is a WEE1 kinase inhibitor with a human IC50 of 9 nM. APO-50815 induces DNA damage, replication stress, S-phase cell accumulation, and apoptosis. APO-50815 can be used for the research of metastatic colorectal cancer.
    APO-50815